Sign In
NewsRadar

Press release centre

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.
   

Past Press Releases - Prosensa B.V.

June 27, 2013
PROSENSA HOLDING B.V. PRICES INITIAL PUBLIC OFFERING
Prosensa Holding B.V. (“Prosensa”) announced today the pricing of its initial public offering of 6,000,000 of its ordinary shares at an initial public offering price of $13.00 per share, before underwriting discounts. More

May 28, 2013
Prosensa Holding B.V. Files Registration Statement for ProposedInitial Public Offering
Prosensa Holding B.V., today announced that it has filed a registration statement on Friday May 24, 2013 on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its ordinary shares. More

March 24, 2011
Results of Prosensa’s extended phase I/II exon-skipping trial in Duchenne Muscular Dystrophy ...
Results of Prosensa’s extended phase I/II exon-skipping trial in Duchenne Muscular Dystrophy published in the New England Journal of Medicine. More

March 30, 2010
Prosensa initiates clinical development of PRO044 in an open label phase I/II study
Prosensa’s second clinical candidate for treatment of Duchenne Muscular Dystrophy. More

March 17, 2010
Prosensa strengthens its management team
Berndt Modig appointed as chief financial officer. More

October 13, 2009
Prosensa and GlaxoSmithKline form alliance to fight Duchenne Muscular Dystrophy
Prosensa, the Dutch based biopharmaceutical company focusing on RNA modulating therapeutics, and GlaxoSmithKline announce that they have entered into an exclusive worldwide collaboration for the development and commercialization of RNA based therapeutics for Duchenne Muscular Dystrophy. More

September 30, 2009
Prosensa and LUMC strengthen strategic alliance through broadened RNA modulation license agreement
Prosensa, the Dutch based biopharmaceutical company focusing on RNA therapeutics and Leiden University Medical Center announce that they have extended their license agreement on RNA modulation. More

September 14, 2009
Prosensa’s RNA based therapeutic PRO051 shows favourable results in the first systemic study ...
Prosensa’s RNA based therapeutic PRO051 shows favourable results in the first systemic study in patients with Duchenne muscular dystrophy. More

August 31, 2009
Prosensa and TREAT-NMD enter into strategic collaboration for PRO-051 clinical trial planning
Prosensa, the Dutch based biopharmaceutical company focusing on RNA modulating therapeutics, announces the successful completion of a feasibility enquiry using the TREAT-NMD Global Database for DMD and the TREAT-NMD Care and Trial Sites Registry for the planning of the phase II/III study for its lead compound PRO-051. More

August 17, 2009
Prosensa receives notice of allowance for key patent related to lead compound
Prosensa receives notice of allowance for key patent related to lead compound in development for Duchenne Muscular Dystrophy. More

Data


26,254
Tech investments
From our Online Data Service
16,957
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Oct 19€3.0MInternet services
Oct 19€6.0MBusiness applications
Oct 18€11.0MConsumer electronics
Oct 18€5.0MBusiness applications
Oct 17€5.9MBiopharmaceuticals
Oct 16€3.7MContent management
Oct 16€7.8MSensors

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.